Danaher agreed to acquire Masimo in a roughly $10 billion cash deal aimed at strengthening its acute‑care monitoring and diagnostics portfolio. The acquisition will fold Masimo’s pulse oximetry and patient‑monitoring technologies into Danaher’s diagnostics and life‑science footprint, reflecting an industry pattern of consolidation to capture integrated clinical data streams. Danaher emphasized strategic fit and potential to scale Masimo’s hospital adoption; investors and competitors will watch integration plans and regulatory clearances closely. The deal underscores private‑market appetite for clinical monitoring assets that can feed diagnostic workflows and hospital decision support.